Expansion to FTC's Orange Book Campaign Leads to Calls for More Clarity from Pharmaceutical Industry
On April 30, the Federal Trade Commission (FTC) announced that it was expanding its campaign against allegedly improper patent listings in the U.S. Food & Drug Administration’s (FDA) Orange Book.